Carfilzomib once-weekly for Multiple Myeloma (ARROW2 Trial)

"Carfilzomib once-weekly is a Phase 3 trial drug, meaning that while there is some data supporting efficacy, multiple rounds of data must support safety in order for it to receive a high score. Our team at Power rates it as a 3."

"Carfilzomib, when administered once a week, is the standard care for treating ophthalmia, sympathetic. It has also been found to be effective in treating branch retinal vein occlusion, macular edema, as well as at least two prior systemic chemotherapy regimens."

"454 individuals with plasma cell neoplasms between the ages of 18 and 99 are eligible for this clinical trial. To meet the requirements for this study, patients must have received previous treatment with a lenalidomide and dexamethasone containing regimen (as long as the subject did not progress during the first 3 months after initiating lenalidomide and dexamethasone containing therapy), Multiple myeloma with documented relapse or progression after most recent myeloma treatment (subjects refractory to the most recent line of therapy are eligible, unless last treatment contained proteasome inhibitor (PI) or lenalidomide"

"The medication carfilzomib was first studied in 2002 at the Manitoba Blood & Marrow Transplant Program CancerCare Manitoba. As of now, there have been 1374 completed studies with 734 active studies. A large concentration of these studies are based in Cincinnati, Ohio."

"According to the eligibility requirements for this study, any person aged 18 to 99 years old may apply to participate."

"This trial is not presently looking for patients, as the most recent update was on March 2nd, 2022. The study was first posted on May 8th, 2019. If you are seeking other trials, there are 826 clinical trials for neoplasms, plasma cell and 734 for Carfilzomib once-weekly that are currently recruiting patients."

"This research is no longer recruiting patients. The listing for this trial was first created on May 8th, 2019 and was last updated on March 2nd, 2022. There are presently 826 studies actively searching for patients with neoplasms, plasma cell and 734 studies for Carfilzomib once-weekly that need participants."